Dr Reddy's Laboratories (BSP:R1DY34) Cash-to-Debt : 3.65 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Dr Reddy's Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Dr Reddy's Laboratories's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.65.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Dr Reddy's Laboratories could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Dr Reddy's Laboratories's Cash-to-Debt or its related term are showing as below:

BSP:R1DY34' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29 Med: 0.85 Max: 5.12
Current: 3.65

During the past 13 years, Dr Reddy's Laboratories's highest Cash to Debt Ratio was 5.12. The lowest was 0.29. And the median was 0.85.

BSP:R1DY34's Cash-to-Debt is ranked better than
67.78% of 1049 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs BSP:R1DY34: 3.65

Dr Reddy's Laboratories Cash-to-Debt Historical Data

The historical data trend for Dr Reddy's Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Dr Reddy's Laboratories Cash-to-Debt Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

0.65

1.17

1.14

1.31

4.59

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.75	4.59	4.72	5.12	3.65

Competitive Comparison of Dr Reddy's Laboratories's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Cash-to-Debt falls into.

Dr Reddy's Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Dr Reddy's Laboratories's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3912.599	/	(772.048	+	80.915)
	=	4.59

Dr Reddy's Laboratories's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4258.472	/	(806.236	+	362.068)
	=	3.65

Dr Reddy's Laboratories (BSP:R1DY34) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Dr Reddy's Laboratories Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (BSP:R1DY34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (BSP:R1DY34) » Definitions » Cash-to-Debt

Traded in Other Exchanges

RDY:USA DRREDDY:India 500124:India RDDA:Germany RDDA:Germany

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (BSP:R1DY34) Headlines

No Headlines